These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 18835576)

  • 1. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
    Lahiri A; Das P; Chakravortty D
    Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs targeting Toll-like receptors.
    Krishnan J; Lee G; Choi S
    Arch Pharm Res; 2009 Nov; 32(11):1485-502. PubMed ID: 20091261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll or toll-free adjuvant path toward the optimal vaccine development.
    Ishii KJ; Akira S
    J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates.
    Ketloy C; Engering A; Srichairatanakul U; Limsalakpetch A; Yongvanitchit K; Pichyangkul S; Ruxrungtham K
    Vet Immunol Immunopathol; 2008 Sep; 125(1-2):18-30. PubMed ID: 18571243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvants and autoimmunity.
    Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
    Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptors' two-edged sword: when immunity meets apoptosis.
    Salaun B; Romero P; Lebecque S
    Eur J Immunol; 2007 Dec; 37(12):3311-8. PubMed ID: 18034428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor ligands energize peptide vaccines through multiple paths.
    Celis E
    Cancer Res; 2007 Sep; 67(17):7945-7. PubMed ID: 17804699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of toll-like receptor therapeutics.
    Parkinson T
    Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR based therapeutics.
    Dunne A; Marshall NA; Mills KH
    Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptors and innate immunity.
    Kumar H; Kawai T; Akira S
    Biochem Biophys Res Commun; 2009 Oct; 388(4):621-5. PubMed ID: 19686699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Toll-like receptors: recognition receptors of the innate immune system and target structures for therapeutical intervention].
    Kabelitz D
    Med Monatsschr Pharm; 2012 Jul; 35(7):238-44. PubMed ID: 22852274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of the innate immune system in domestic animals.
    Coffey TJ; Werling D
    Cell Tissue Res; 2011 Jan; 343(1):251-61. PubMed ID: 20953632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating vaccine responses with dendritic cells and Toll-like receptors.
    Pulendran B
    Immunol Rev; 2004 Jun; 199():227-50. PubMed ID: 15233738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
    Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell-dependent and -independent IgA responses: role of TLR signalling.
    Bessa J; Bachmann MF
    Immunol Invest; 2010; 39(4-5):407-28. PubMed ID: 20450285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic and therapeutic implications of toll-like receptor ligands.
    Hedayat M; Takeda K; Rezaei N
    Med Res Rev; 2012 Mar; 32(2):294-325. PubMed ID: 22383179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
    Makkouk A; Abdelnoor AM
    Immunopharmacol Immunotoxicol; 2009; 31(3):331-8. PubMed ID: 19555209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Toll-like receptors].
    Essakalli M; Atouf O; Bennani N; Benseffaj N; Ouadghiri S; Brick C
    Pathol Biol (Paris); 2009 Jul; 57(5):430-8. PubMed ID: 18513891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous TLR ligands and autoimmunity.
    Wagner H
    Adv Immunol; 2006; 91():159-73. PubMed ID: 16938540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.